Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid
Avtorji:ID Kmetec, Andrej (Avtor)
ID Hajdinjak, Tine (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (410,07 KB)
MD5: EBA738181F961BD1385D090B91E5A9C3
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background. The aim of the study was evaluation of zoledronic acid with regard to safety, effect on analgesic consumption and impact on occurrence of skeletal related events in patients with bone lesions from solid tumors and multiple myeloma.Methods. We conducted an observational, 12-month, phase IV and multi-center study. One hundred and twenty-five symptomatic (pain) bone-metastatic patients were included between 2007 and 2009: 92 prostate cancers, 28 multiple myelomas, 5 others. They were prescribed monthly infusions of zoledronic acid in accordance to each diseases treatment guidelines. Analgesics consumption, pain and laboratory values were evaluated.Results. Zoledronic acid was prescribed concurrent to initial therapy for myeloma and only in late stage of prostate cancer. With treatment, percentage of patients on analgesics decreased in myeloma group (from 57% to 24%) and increased in prostate cancer group (from 70% to 88%). In patients with any analgesics, the use of opiates prescriptiondropped from 72.9% to 64%, percentages of non-steroidal analgesics and other mild analgesics increased slightly. Pain score (Visual Analog Scale, VAS) decreased non significantly (by 22%) in prostate cancer but significantly in myeloma (by 97%). Hypocalcaemia grade 3 or 4 was observed in 4% of patients. Deviations in creatinine remained stable throughout. A total of 31 skeletal related events were reported for 10 patients (8%).Conclusions. Zoledronic acid was safe medication. Different response of pain was seen between prostate cancer and myeloma patients, which might be due to different stages of disease where it was prescribed according to present guidelines. Possibility of earlier start of treatment should be explored in prostate cancer.
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.09.2013
Založnik:Association of Radiology and Oncology
Leto izida:2013
Št. strani:str. 289-295, VI
Številčenje:Vol. 47, no. 3
Izvor:Ljubljana
PID:20.500.12556/DiRROS-18596 Novo okno
UDK:616-006-085:615.212
ISSN pri članku:1318-2099
COBISS.SI-ID:269154048 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:03.04.2024
Število ogledov:547
Število prenosov:142
Metapodatki:XML DC-XML DC-RDF
:
KMETEC, Andrej in HAJDINJAK, Tine, 2013, Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid. Radiology and oncology [na spletu]. 2013. Vol. 47, no. 3, p. 289–295, vi. [Dostopano 2 april 2025]. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=18596
Kopiraj citat
  
Objavi na:Bookmark and Share



Podobna dela iz ostalih repozitorijev:

Ni podobnih del

Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:rak (medicina), bolniki, zasevki, bolečina, analgetiki


Nazaj